News & Recipes

Let’s Beat Therapy Resistant Breast Cancer

Did you know Estrogen receptor positive breast cancer is the most common breast cancer, making up 75 per cent of all diagnoses of this devastating disease?

Thanks to vital research, women living with this breast cancer do have a targeted treatment available to them. Unfortunately many do develop resistance to this treatment, and without access to any other treatment options, they can only undergo chemotherapy.

Now, with your forktastic support of The Longest Table these women have hope.

Meet Dr Theresa Hickey from the Dame Roma Mitchell Cancer Research Laboratories at the University of Adelaide. She is pioneering vital research to better understand why patients develop therapy resistance in the hope of coming up with new treatment options to combat this fatal form of the disease.

“We believe that breast cancer represents a state of hormone imbalance and are exploring whether restoring this balance will be an effective, less toxic way of treating or preventing estrogen receptor positive breast cancer,” Dr Hickey said.

Estrogen receptor positive breast cancer occurs when the cancer cells grow in response to the sex hormone estrogen. These cancers also commonly have other sex hormone receptors, including androgen and progesterone receptors.

“Breast cancers that have all three sex hormone receptors are much more likely to respond to anti-estrogen therapy than those that have estrogen receptor alone. Those that have estrogen receptor and just one other sex hormone receptor lie in between these extremes in terms of therapy response,” Theresa said.

“We know that the major cause of death from breast cancer is resistance to current estrogen receptor target therapies, so through our research we are developing alternative approaches to treat or prevent therapy resistant disease.”

Dr Hickey’s research will save lives! You can help her simply by hosting a dinner with your friends through The Longest Table. Register today!